Limits...
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis.

Zhang X, Wu J - Prostate Int (2015)

Bottom Line: Pooled hazard ratios of miR-145 and 95% confidence intervals were calculated.Four studies with a total of 211 patients were included in this meta-analysis.Thus, lower miR-145 expression was found to significantly predict poorer outcomes.

View Article: PubMed Central - PubMed

Affiliation: Shanxi Medical University, Taiyuan, China.

ABSTRACT

Background: Many studies have shown that microRNAs (miRNAs) exhibit altered expression in various cancers and may play an important role as prognostic biomarkers. The present meta-analysis was undertaken to summarize recent studies of the use of microRNA-145 (miR-145) in the assessment of prostate cancer and to analyze the prognostic role of miR-145 for disease-free survival (DFS) outcome.

Methods: The present meta-analysis was performed by searching PubMed with the use of multiple search strategies. Data were extracted from studies examining DFS in patients with prostate cancer who showed lower expression of miR-145. Pooled hazard ratios of miR-145 and 95% confidence intervals were calculated. Four studies with a total of 211 patients were included in this meta-analysis.

Results: For overall DFS, the pooled hazard ratio of lower miR-145 expression in prostate cancer was 0.74 (95% confidence interval: 0.23-2.34, P = 0.001). Thus, lower miR-145 expression was found to significantly predict poorer outcomes.

Conclusions: The present findings suggest that downregulation of the expression of miR-145 might predict poor prognosis in patients with prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Study selection process.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588372&req=5

fig1: Study selection process.

Mentions: This meta-analysis was carried out in accordance with the guidelines of the Meta-analysis of Observational Studies in Epidemiology Group.19 The PubMed and Medline databases were searched for the last time in May 2014, and no lower date limit was used. Only reviews published in English were evaluated. The following search strategy was used: (“microRNA-145” OR “miR-145” OR “miRNA-145”) AND (“prostate cancer” OR “prostate carcinoma” OR “PCa”) AND (”prognosis” OR “prognosis”). Eligible studies were included in the meta-analysis if they met the following criteria: (1) they had to discuss patients with PCa; (2) they had to measure miR-145 expression in tumor tissue; (3) they had to investigate DFS outcome or the correlation between miR-145 expression and clinical variables; and (4) the method of miR-145 detection had to be the same. Articles were excluded on the basis of any of the following criteria: (1) they were review articles, letters, or laboratory articles; (2) they were not in English; (3) they lacked key information for calculation by use of methods established by Parmar et al,20 Tierney et al21; Williamson et al,22 and (4) they were repeat studies that included the same author and the same samples from the same patients as in a study already included. Two reviewers (X.Z. and J.W.) independently evaluated the titles and abstracts of the identified articles in duplicate. A flow diagram of the study selection process is presented in Fig. 1.


Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis.

Zhang X, Wu J - Prostate Int (2015)

Study selection process.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588372&req=5

fig1: Study selection process.
Mentions: This meta-analysis was carried out in accordance with the guidelines of the Meta-analysis of Observational Studies in Epidemiology Group.19 The PubMed and Medline databases were searched for the last time in May 2014, and no lower date limit was used. Only reviews published in English were evaluated. The following search strategy was used: (“microRNA-145” OR “miR-145” OR “miRNA-145”) AND (“prostate cancer” OR “prostate carcinoma” OR “PCa”) AND (”prognosis” OR “prognosis”). Eligible studies were included in the meta-analysis if they met the following criteria: (1) they had to discuss patients with PCa; (2) they had to measure miR-145 expression in tumor tissue; (3) they had to investigate DFS outcome or the correlation between miR-145 expression and clinical variables; and (4) the method of miR-145 detection had to be the same. Articles were excluded on the basis of any of the following criteria: (1) they were review articles, letters, or laboratory articles; (2) they were not in English; (3) they lacked key information for calculation by use of methods established by Parmar et al,20 Tierney et al21; Williamson et al,22 and (4) they were repeat studies that included the same author and the same samples from the same patients as in a study already included. Two reviewers (X.Z. and J.W.) independently evaluated the titles and abstracts of the identified articles in duplicate. A flow diagram of the study selection process is presented in Fig. 1.

Bottom Line: Pooled hazard ratios of miR-145 and 95% confidence intervals were calculated.Four studies with a total of 211 patients were included in this meta-analysis.Thus, lower miR-145 expression was found to significantly predict poorer outcomes.

View Article: PubMed Central - PubMed

Affiliation: Shanxi Medical University, Taiyuan, China.

ABSTRACT

Background: Many studies have shown that microRNAs (miRNAs) exhibit altered expression in various cancers and may play an important role as prognostic biomarkers. The present meta-analysis was undertaken to summarize recent studies of the use of microRNA-145 (miR-145) in the assessment of prostate cancer and to analyze the prognostic role of miR-145 for disease-free survival (DFS) outcome.

Methods: The present meta-analysis was performed by searching PubMed with the use of multiple search strategies. Data were extracted from studies examining DFS in patients with prostate cancer who showed lower expression of miR-145. Pooled hazard ratios of miR-145 and 95% confidence intervals were calculated. Four studies with a total of 211 patients were included in this meta-analysis.

Results: For overall DFS, the pooled hazard ratio of lower miR-145 expression in prostate cancer was 0.74 (95% confidence interval: 0.23-2.34, P = 0.001). Thus, lower miR-145 expression was found to significantly predict poorer outcomes.

Conclusions: The present findings suggest that downregulation of the expression of miR-145 might predict poor prognosis in patients with prostate cancer.

No MeSH data available.


Related in: MedlinePlus